cdk2 inhibitor incb123667
cdk2 inhibitor incb123667: 7 clinical trials tracked.
cdk2 inhibitor incb123667 evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about cdk2 inhibitor incb123667, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (7)
A Phase 3, Double-Blind, Randomized, Controlled Study of INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1 (MAESTRA 3)
Primary endpoint: Progression-Free Survival (PFS) by BICR
A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
Primary endpoint: PK for plasma INCB123667: Cmax
A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
Primary endpoint: PK for plasma INCB123667: Cmax
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Primary endpoint: Progression-Free Survival (PFS) by BICR
An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants
Primary endpoint: Total Recovery (Urine + Feces) of the Administered Radioactivity
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
Primary endpoint: Objective Response by IRC
A Phase 1, Open-Label Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB123667